查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654329

全球止血診斷市場：市場規模、佔有率、趨勢分析（按產品、測試、最終用途和地區）、細分市場預測（2025-2030 年）

Hemostasis Diagnostics Market Size, Share & Trends Analysis Report By Product (POC Testing Systems, Consumables), By Test (Prothrombin Time Test, D Dimer Test), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

止血診斷市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球止血診斷市場規模預計到2030年將達到14.9億美元，2025年至2030年複合年成長率為4.5%。

由於全球老年人口增加、診斷技術的進步、對出血和凝血障礙的認知不斷提高以及慢性病患病率上升等各種因素，市場可能會呈現顯著成長。

推動市場發展的因素之一是老年人口的不斷成長。隨著人口老化，患有影響止血的疾病的可能性增加，例如靜脈血栓栓塞症、心房顫動和其他心血管疾病。老年人也更有可能接受需要精確監測凝血程度的手術，以避免過度出血和血栓形成等併發症。這些人口趨勢正在推動對能夠評估血液凝固和出血風險的診斷工具的需求。

產品開發技術的進步也促進了市場的發展。先進、準確的診斷分析儀（如照護現場設備）的開發使得醫療保健提供者能夠更容易地在各種醫療環境中快速監測凝血參數。這些進步提高了診斷止血疾病的速度和效率，這在緊急和緊急醫療環境中尤其重要。

此外，自動分析儀和分子診斷測試等測試平台的創新擴大了可用的測試範圍，並且可以更準確地檢測出血和凝血障礙的根本原因。

由於新興國家正在進行的研究，人們對出血性疾病的認知和理解不斷提高，從而推動了治療藥物市場的成長。公共衛生宣傳活動和醫學研究強調了早期診斷和介入對於血友病、深層靜脈栓塞症（DVT）和肺動脈栓塞等疾病管理的重要性。因此，人們越來越重視對有這些疾病風險的患者進行定期篩檢和監測，從而增加了對止血診斷測試的需求。

慢性病，特別是心血管系統相關疾病的發生率不斷上升，也促進了市場的成長。心血管疾病常常導致凝血障礙，這是由於動脈中血栓形成以及使用抗凝血療法來預防中風和心臟病發作造成的。隨著越來越多的人被診斷出患有慢性心血管疾病，對能夠監測血液凝固和出血風險的診斷測試的需求也日益增加，從而進一步推動市場的發展。

此外，個人化醫療的興起正在對止血診斷市場產生影響。在止血方面，個人化醫療可以幫助識別出血和血液凝固障礙高風險的患者，從而使醫療保健提供者能夠選擇最合適的診斷測試和治療方法。這一趨勢正在推動更具針對性的診斷工具的開發，以滿足個別患者的特定需求。

市場的主要企業包括 F. Hoffmann-La Roche AG、丹納赫集團、Sysmex 公司、西門子醫療、Horiba Medical、Haemonetics 公司、HemoSonics, LLC、Sterile Safequip and Chemicals LLP、TECO Medical Instruments 和 Stago。這些公司選擇的主要策略包括產品開發創新，例如推出更先進的自動化照護現場診斷設備，以提供更快、更準確的結果。與醫院、研究機構和其他醫療保健提供者建立策略聯盟和合作對於擴大我們的市場範圍和增強我們的產品供應也至關重要。此外，每家公司都致力於擴大產品系列，以涵蓋更廣泛的診斷測試，以滿足常規和特殊測試需求。

止血診斷市場：分析概述

  • 按產品類型分類，消耗品將佔據最大的銷售佔有率，到 2024 年將達到 61.1%。隨著測試數量的增加，預測期內對消耗品的需求可能會呈現良好的成長。
  • 根據測試，凝血酶原時間測試將佔據市場主導地位，到 2024 年將佔據 31.5% 的最大佔有率。 PT 測試可以在各種醫療保健環境中進行，包括醫院、診所甚至照護現場，更容易及時診斷和治療。此外，此測試的周轉時間相對較短，可讓臨床醫生快速做出有關患者護理的決策。
  • 根據最終用途，醫院部門佔據市場主導地位，2024 年的收入佔有率最大，為 57.7%。這一領域佔據主導地位，是因為醫院中接受檢測的患者數量龐大。
  • 北美憑藉完善的醫療保健基礎設施佔據了全球市場的主導地位，能夠及時診斷和管理患有出血和凝血障礙的患者。
  • 預計亞太地區將以最快的速度成長，2025 年至 2030 年的預測期內複合年成長率為 5.1%。這是由於新興市場醫療設施的增加。此外，對預防性常規檢測的日益關注也支持了市場的成長。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第 3 章 止血診斷市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 止血診斷市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 止血診斷市場：按產品分類的估計與趨勢分析

  • 按產品市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球止血診斷市場（按產品）展望
  • 市場規模預測及趨勢分析（2018-2030年）
    • 實驗室分析設備
    • 就地檢驗系統
    • 耗材

第 5 章 止血診斷市場：測試估計與趨勢分析

  • 測試市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球止血診斷市場前景（按測試）
  • 市場規模預測及趨勢分析（2018-2030年）
    • 活化部份凝血活酵素時間
    • D-二聚體檢測
    • 纖維蛋白原檢測
    • 凝血酶原時間 (PT) 測試
    • 其他測試

第 6 章止血診斷市場：按最終用途的估計和趨勢分析

  • 按最終用途分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板
  • 全球止血診斷市場前景（依最終用途分類）
  • 市場規模預測及趨勢分析（2018-2030年）
    • 醫院
    • 診斷實驗室
    • 其他

第 7 章 止血診斷市場：按地區分類的估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 區域控制面板
  • 全球止血診斷市場區域展望
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • Key company market share analysis, 2024
    • F. Hoffmann-La Roche AG
    • Danaher Corporation
    • Sysmex Corporation
    • Siemens Healthineers
    • Horiba Medical
    • Haemonetics Corporation
    • HemoSonics, LLC
    • Sterile Safequip and Chemicals LLP
    • TECO Medical Instruments
    • Stago
Product Code: GVR-4-68040-502-3

Hemostasis Diagnostics Market Growth & Trends:

The global hemostasis diagnostics market size is expected to reach USD 1.49 billion by 2030, registering a CAGR of 4.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is likely to show significant growth due to various factors, such as the growing geriatric population across the globe, advancements in diagnostic technologies, increasing awareness of bleeding and clotting disorders, and the rising prevalence of chronic diseases.

One of the primary drivers of the market is the growing geriatric population. As people age, the likelihood of developing conditions that affect hemostasis, such as venous thromboembolism, atrial fibrillation, and other cardiovascular diseases, increases. Older individuals are also more likely to undergo surgeries that require accurate monitoring of coagulation levels to avoid complications like excessive bleeding or clot formation. This demographic trend is boosting the demand for diagnostic tools that can assess blood clotting and bleeding risks.

Technological advancements in terms of product development are also contributing to market growth. The development of sophisticated and accurate diagnostic analyzers, such as point-of-care devices, has made it easier for healthcare providers to quickly monitor coagulation parameters across various healthcare settings. These advancements have improved the speed and efficiency of diagnosing hemostasis disorders, which is particularly important in emergency and critical care settings.

In addition, innovations in testing platforms, such as automated analyzers and molecular diagnostic tests, have expanded the range of tests available, allowing for more precise detection of underlying causes of bleeding and clotting disorders.

Increased awareness and better understanding of bleeding disorders owing to continuous research in emerging economies are driving the growth of the hemostasis diagnostics market. Public health campaigns and medical research have highlighted the importance of early diagnosis and intervention in managing conditions such as hemophilia, deep vein thrombosis (DVT), and pulmonary embolism. As a result, there is a greater emphasis on regular screening and monitoring of patients at risk of these conditions, which increases the demand for hemostasis diagnostic tests.

The rising prevalence of chronic diseases, particularly those related to the cardiovascular system, is also contributing to the growth of the market. Cardiovascular diseases often lead to clotting disorders, either due to the formation of blood clots in the arteries or the use of anticoagulant therapies to prevent strokes and heart attacks. As more individuals are diagnosed with chronic cardiovascular conditions, there is an increased need for diagnostic tests that can monitor blood clotting and bleeding risks, further driving the market.

Furthermore, the growing adoption of personalized medicine is playing a role in the hemostasis diagnostics market. In the context of hemostasis, personalized medicine can help identify patients who are at higher risk of bleeding or clotting disorders, enabling healthcare providers to choose the most appropriate diagnostic tests and treatments. This trend is encouraging the development of more targeted diagnostic tools that can cater to the specific needs of individual patients.

Some key players in the market are F. Hoffmann-La Roche AG; Danaher Corporation; Sysmex Corporation; Siemens Healthineers; Horiba Medical; Haemonetics Corporation; HemoSonics, LLC; Sterile Safequip and Chemicals LLP; TECO Medical Instruments; Stago and more. Key strategies opted by the companies include innovation in product development, such as introducing more advanced, automated, and point-of-care diagnostic devices that offer faster, more accurate results. Strategic partnerships and collaborations with hospitals, research institutions, and other healthcare providers are also crucial for expanding market reach and enhancing product offerings. Additionally, companies are focusing on expanding their product portfolios to include a broader range of diagnostic tests, catering to both routine and specialized testing needs.

Hemostasis Diagnostics Market Report Highlights:

  • Based on product, consumables accounted for the largest revenue share of 61.1% in 2024. With the increasing number of tests being performed, the demand for consumables is likely to show lucrative growth over the forecast period.
  • Based on test, the prothrombin time test dominated the market and accounted for the largest share of 31.5% in 2024.The PT test can be performed in various healthcare settings, including hospitals, clinics, and even point-of-care locations, making it accessible for timely diagnosis and treatment. Additionally, the test has a relatively short turnaround time, allowing clinicians to make rapid decisions regarding patient care.
  • Based on end use, the hospitals segment dominated the market with the largest revenue share of 57.7% in 2024. The segment dominance is attributed to large patient volumes being tested in hospitals.
  • North America dominated the global market owing to well-established healthcare infrastructure allowing timely diagnosis and management of patients with bleeding and clotting disorders.
  • The Asia Pacific region is expected to witness the fastest growth with a CAGR of 5.1% over the forecast period from 2025 to 2030, due to the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is also supporting the market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Test
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. Product outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hemostasis Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Bleeding Disorders
      • 3.2.1.2. Technological Advancements
      • 3.2.1.3. Awareness of Preventive Healthcare
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Devices
      • 3.2.2.2. Lack of Skilled Personnel
  • 3.3. Hemostasis Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Hemostasis Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Hemostasis Diagnostics Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Laboratory Analyzers
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Automated Systems
        • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Semi-automated Systems
        • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Manual Systems
        • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Point-of-Care Testing Systems
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Hemostasis Diagnostics Market: Test Estimates & Trend Analysis

  • 5.1. Test Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Hemostasis Diagnostics Market by Test Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Activated Partial Thromboplastin Time
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. D-Dimer Test
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Fibrinogen Test
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Prothrombin Time (PT) Test
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Other Tests
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Hemostasis Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Hemostasis Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Diagnostic Laboratories
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Hemostasis Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Target disease prevalence
      • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Target disease prevalence
      • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Target disease prevalence
      • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Target disease prevalence
      • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Target disease prevalence
      • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Target disease prevalence
      • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Target disease prevalence
      • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Target disease prevalence
      • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Target disease prevalence
      • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. Target disease prevalence
      • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Target disease prevalence
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Target disease prevalence
      • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Target disease prevalence
      • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2024
    • 8.3.2. F. Hoffmann-La Roche AG
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Danaher Corporation
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Sysmex Corporation
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Siemens Healthineers
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Horiba Medical
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Haemonetics Corporation
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. HemoSonics, LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Sterile Safequip and Chemicals LLP
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. TECO Medical Instruments
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Stago
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table. 1 List of Abbreviation
  • Table. 2 North America hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 3 North America hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 4 North America hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 5 U.S. hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 6 U.S. hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 7 U.S. hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 8 Canada hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 9 Canada hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 10 Canada hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 11 Mexico hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 12 Mexico hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 13 Mexico hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 14 Europe hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 15 Europe hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 16 Europe hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 17 UK hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 18 UK hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 19 UK hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 20 Germany hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 21 Germany hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 22 Germany hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 23 France hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 24 France hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 25 France hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 26 Italy hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 27 Italy hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 28 Italy hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 29 Spain hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 30 Spain hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 31 Spain hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 32 Denmark hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 33 Denmark hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 34 Denmark hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 35 Sweden hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 36 Sweden hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 37 Sweden hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 38 Norway hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 39 Norway hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 40 Norway hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 41 Asia Pacific hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 42 Asia Pacific hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 43 Asia Pacific hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 44 Japan hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 45 Japan hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 46 Japan hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 47 China hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 48 China hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 49 China hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 50 India hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 51 India hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 52 India hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 53 Australia hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 54 Australia hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 55 Australia hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 56 Thailand hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 57 Thailand hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 58 Thailand hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 59 South Korea hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 60 South Korea hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 61 South Korea hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 62 Latin America hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 63 Latin America hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 64 Latin America hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 65 Brazil hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 66 Brazil hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 67 Brazil hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 68 Argentina hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 69 Argentina hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 70 Argentina hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 71 Middle East & Africa hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 72 Middle East & Africa hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 73 Middle East & Africa hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 74 South Africa hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 75 South Africa hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 76 South Africa hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 77 Saudi Arabia hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 78 Saudi Arabia hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 79 Saudi Arabia hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 80 UAE hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 81 UAE hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 82 UAE hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table. 83 Kuwait hemostasis Diagnostics market, by test, 2018 - 2030 (USD Million)
  • Table. 84 Kuwait hemostasis Diagnostics market, by product, 2018 - 2030 (USD Million)
  • Table. 85 Kuwait hemostasis Diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hemostasis Diagnostics: Market outlook
  • Fig. 9 Hemostasis Diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Hemostasis Diagnostics Market driver impact
  • Fig. 15 Hemostasis Diagnostics Market restraint impact
  • Fig. 16 Hemostasis Diagnostics Market strategic initiatives analysis
  • Fig. 17 Hemostasis Diagnostics market: Product movement analysis
  • Fig. 18 Hemostasis Diagnostics market: Product outlook and key takeaways
  • Fig. 19 Laboratory Analyzers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Point-of-Care Testing Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Automated Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Semi-automated Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Manual Systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Hemostasis Diagnostics market: Test movement analysis
  • Fig. 26 Hemostasis Diagnostics market: Test outlook and key takeaways
  • Fig. 27 Activated Partial Thromboplastin Time market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 D-Dimer Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Fibrinogen Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Prothrombin Time (PT) Test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Other Tests market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Hemostasis Diagnostics market: End Use movement analysis
  • Fig. 33 Hemostasis Diagnostics market: End Use outlook and key takeaways
  • Fig. 34 Hospitals hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Diagnostic Laboratories hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Others hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 North America hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Canada hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Germany hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 France hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Italy hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Spain hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Norway hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Japan hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 India hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Australia hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Thailand hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Argentina hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Middle East and Africa. hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 UAE hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Kuwait hemostasis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)